Latest news with #Orforglipron
Yahoo
14-05-2025
- Health
- Yahoo
New Diet Pill Shows Similar Effects to Ozempic
Whether it's drawing blood or administering medication, needles scare many people, and not everyone can imagine doing it themselves. However, when it comes to severe obesity and Type 2 diabetes, GLP-1 receptor agonists—such as Ozempic and Wegovy—are effective aids. The catch: the medication must be regularly injected with a needle. But a new 'weight loss pill' could soon replace this method. Is the pill for obesity coming? Pharmaceutical company Eli Lilly has released initial Phase 3 results for Orforglipron—the world's first oral GLP-1 pill that significantly lowers blood sugar and reduces weight. Phase 3 studies are the final stage before potential approval, testing a drug's efficacy and safety. Orforglipron's effects are comparable to existing GLP-1 treatments that require injections. According to the World Health Organization (WHO), one in eight people worldwide suffered from obesity in 2022. This form of overweight is defined by a body mass index of 30 or higher. Among adults, obesity cases have more than doubled globally since 1990, and among adolescents, they have quadrupled.1 Consequently, the risk of diseases such as type 2 diabetes, cardiovascular diseases, cancer, and others increases. As future projections—cautiously stated—do not look promising, immediate measures to address this health crisis are necessary, according to the medical journal The Lancet.2 Chugai Pharmaceutical developed Orforglipron in 2018, later licensed by Eli Lilly. The active ingredient belongs to the group of GLP-1 receptor agonists—medications that mimic the body's hormone GLP-1 to regulate blood sugar levels, reduce hunger, and delay gastric emptying. Unlike known injectable substances like semaglutide, found in Ozempic, Orforglipron is based on a small molecule rather than a peptide. This is the crucial difference: It is not immediately broken down in the digestive tract and can therefore be taken as a pill. One pill per day is required, with no dietary restrictions. The simple form of administration could present a lower barrier for many affected individuals compared to regular injections. The pharmaceutical company tested Orforglipron in the Phase 3 study ACHIEVE-1. This clinical trial involved 559 overweight adults with type 2 diabetes whose blood sugar levels were not within the desired range despite diet and exercise. The HbA1c value, which provides information about blood sugar over the past two to three months, served as a marker. In healthy individuals, this value is about 5.7 percent. For type 2 diabetics, values between 6.5 and 7.5 percent are targeted in therapy.3 However, at the start of the study, participants had an average HbA1c value of 8.0 percent and weighed around 90 kilograms. They were randomly assigned to one of four groups: three different dosages of Orforglipron (3, 12, and 36 milligrams) or a placebo. The treatment lasted 40 weeks. All participants started with a low initial dose and gradually increased to the target amount. The goal was to evaluate the blood sugar-lowering effect of the medication compared to placebo. No other diabetes medications were taken during this time. Indeed, Orforglipron showed a significant reduction in HbA1c values across all dosages. The average decrease ranged from 1.3 to 1.6 percentage points, an effect comparable to injectable GLP-1 agents like semaglutide. Over 65 percent of participants receiving the highest dose achieved an HbA1c value of 6.5 percent or lower—below the diabetes threshold. The question now on everyone's mind: Does the pill work as well against obesity as the injections? The study showed that participants lost an average of 7.3 kilograms, about eight percent of their initial weight. However, tirzepatide demonstrated a higher weight loss of 16 to 21 percent in approval studies.4 Ozempic also achieved a notable 15 percent after just over a year of use.5 Eli Lilly's press release notes that the weight loss of their participants is not yet complete, meaning the plateau has not been reached. The potential effect could exceed eight percent—but that remains to be seen.6 Despite oral administration, Orforglipron's side effects are similar to those of known GLP-1 therapies. Gastrointestinal issues were most common, including nausea, vomiting, diarrhea, and constipation. These side effects were mostly mild to moderate and led to therapy discontinuation in only a few cases. Discontinuation rates due to adverse events ranged from four to eight percent—compared to one percent in the placebo group. Cardiologist Professor Naveed Sattar from the University of Glasgow sees great potential in the study results. 'These are important findings. New oral agents that lower blood sugar and significantly reduce weight beyond the levels of most existing diabetes therapies are crucial for the future treatment of type 2 diabetes. Current research has shown that obesity not only leads to type 2 diabetes in many people but also significantly contributes to many associated complications. Targeted weight loss often also improves patients' quality of life,' he commented.7 However, Sattar also emphasizes that not all questions have been answered: 'One caveat is that we do not yet know the effects of this newer therapy on cardiovascular events, but future studies will show this. It is also encouraging to learn about the safety profile of these new oral GLP-1RA medications—especially regarding liver values—and we look forward to seeing the data in a full publication in due course.' The results of the ACHIEVE-1 study will be presented at this year's American Diabetes Association annual meeting in June and are set to be published in a scientific journal. Lilly also plans to release more data from the clinical Phase 3 study series 'ACHIEVE' soon. Additionally, new results from the parallel study 'ATTAIN,' which specifically investigates Orforglipron for weight control, will be available soon. Eli Lilly plans to apply for approval for the treatment of obesity with the U.S. Food and Drug Administration (FDA) later this year, followed by an application for diabetes treatment in early 2026. The company emphasizes that no supply shortages are expected upon approval. Weltgesundheitsorganisation (WHO). Obesity and overweight. (accessed May 13, 2025) ↩︎ Kerr, J. A. et al. (2021). Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study. The Lancet. ↩︎ Helios. Blutzuckerwerte und ihre Bedeutung. (accessed May 14, 2025) ↩︎ Wilding, J.P.H., et al. (2022). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine., et al. (2022). Once-Weekly Semaglutide in Adults With Overweight or Obesity. New England Journal of Medicine. ↩︎ Wilding, J. P. H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. ↩︎ Eli Lilly. Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial. (accessed May 14, 2025) ↩︎ UK Science Media Centre. expert reaction to top line results in Lilly press release about their phase 3 ACHIEVE-1 trial of their oral GLP-1 (orforglipron) and weight loss efficacy, and safety. (accessed May 14, 2025). ↩︎ The post New Diet Pill Shows Similar Effects to Ozempic appeared first on FITBOOK.
Yahoo
01-05-2025
- Business
- Yahoo
Why Eli Lilly (LLY) Stock Is Nosediving
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due to lower-than-expected profitability and full-year EPS guidance that missed significantly. On the other hand, Eli Lilly narrowly topped analysts' revenue expectations, fueled by surging demand for Mounjaro and Zepbound, which together drove a 45% year-over-year increase in total sales. Still, this was a softer quarter. The shares closed the day at $794.09, down 11.4% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Eli Lilly? Access our full analysis report here, it's free. Eli Lilly's shares are not very volatile and have only had 8 moves greater than 5% over the last year. Moves this big are rare for Eli Lilly and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 14 days ago when the stock gained 15.3% on the news that results from a Phase 3 trial showed that its experimental drug, Orforglipron, performed significantly well in helping patients manage obesity and diabetes. The stock's reaction suggested that investors were optimistic that, if approved, Lilly could scale production quickly and tap into the fast-growing diabetes and obesity markets. Eli Lilly is up 2.3% since the beginning of the year, but at $796.33 per share, it is still trading 17.1% below its 52-week high of $960.02 from August 2024. Investors who bought $1,000 worth of Eli Lilly's shares 5 years ago would now be looking at an investment worth $5,183. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
30-04-2025
- Business
- Yahoo
PepsiCo CEO was grilled about GLP-1s by a 13-year-old on his Q1 conference call
The 13-year-old daughter of a Jefferies analyst asked about the effect of GLP-1 oral medications during PepsiCo's most recent quarterly earnings call, as part of 'Bring your Kid to Work Day.' CEO Ramon Laguarta took the question seriously, saying his company was marketing snacks in smaller portions to target consumers with smaller appetites. PepsiCo CEO Ramon Laguarta was no doubt expecting tough questions during the company's Q1 earnings call; what he probably wasn't expecting was to be interrogated about the effect of pharmaceuticals on the human digestive system by a 13-year-old. Amid inquiries on revenue, tariffs, and volumes that could have comprised any other earnings call that day, Jefferies analyst Kaumil Gajrawala surprised Laguarta by letting his daughter Milena Gajrawala ask a question. 'Hey guys, it's 'Bring Your Kid to Work Day' at Jefferies. So, if you don't mind, my daughter Milena's going to ask the question,' Gajrawala said. Far from lobbing a softball question, the 13-year-old Milena Gajrawala struck at a core issue for PepsiCo and other food companies: the threat of weight-loss inducing GLP-1 medications that curb the appetites of consumers. 'So what do you think about the launch of GLP-1 oral medications coming to market next year?' she asked. Before answering, Laguarta said, 'That's awesome,' and then launched into a serious response that highlighted the company's 'fiber and hydration solutions.' 'We thought Milena asked a fair question and Ramon was happy to answer it. Hearing from her was a pleasant surprise on what is always a busy day," a PepsiCo spokesperson said in a statement to Fortune. The younger Gajrawala mentioned oral GLP-1 medications, one of which—orforglipron by Eli Lilly—is already in late-stage clinical trials. Orforglipron's potential advantage is that it is an oral medication—competitor Ozempic requires regular injections—but has a similar weight-loss effect. The drug could thus supercharge the adoption of this class of medication, which helps suppress appetite and is already cutting into the profits of snack makers and other food companies. Laguarta mentioned that another way the company is battling a potential GLP-1 slump is by emphasizing its smaller-portion snacks. 'They're eating less quantities, so our offerings in the small portions and whether it's in multipack or some other options that we provide keeps our brands in their repertoire and it's still relevant,' he said in response to Gajrawala's question. On another earnings call that day, Gajrawala also let his son, 13-year-old Kamran Gajrawala, get in on the action. Kamran Gajrawala asked the CEO of Keurig Dr Pepper a question about Dr Pepper's new blackberry-flavored soda. 'Wow, fantastic. I think it's my first ever question from a young person, and I appreciate it, Kamran. And I hope Kamran is a big fan of Dr Pepper Blackberry,' CEO Tim Cofer said. Wall Street has a venerable history of extracting investment wisdom from teenagers. In 2009, 15-year-old Matthew Robson, an intern at Morgan Stanley, was allowed to write a research note on how he and his friends consumed media. He reported that they didn't read newspapers and that few watched TV. None of them used Twitter, he wrote. And earlier this year Fortune asked a 14-year-old to canvass her friends on why they stopped trusting traditional media in favor of influencers they know are unreliable. Influencers feel like trustworthy friends, whereas adults are the enemy, she found. This story was originally featured on
Time of India
25-04-2025
- Business
- Time of India
Tata Consumer, Bajaj Housing Finance & more: Top stocks on brokers' radar for April 25
Representative image Citigroup has given a 'buy' rating on Divis Laboratories with the target price at Rs 7,050. Analysts feel the company has high potential to become the primary supplier given capacity addition. Orforglipron, Eli Lilly's potential best-in-class oral GLP-1, is the next addition in Divi's pipeline. They expect more rounds of capex with scale up in products. The stock is the top pharma pick. CLSA has a 'hold' call on Tata Consumer with a target price of Rs 1,044. Analysts said Jan-March net sales was up 17% on the year which was broadly in-line, along with the company's gross profit. However, gross margin missed guidance due to high input costs while EBITDA was below estimates due to higher other expenses. ICICI Securities has retained its 'hold' rating on LTIMindtree with a revised target price of Rs 4,410. Analysts said LTIM reported muted performance for Jan-March with lower revenue growth. Slower growth came on the back of delayed ramp-up and deferral of deals, ramp-down in healthcare vertical, top-5 clients' revenue declining from AI-led gain sharing. LTIM expects the deferred deals to come through in the current quarter. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trade Bitcoin & Ethereum – No Wallet Needed! IC Markets Start Now Undo CEO designate's three-pronged strategic emphasis on efficiency is expected to improve margin. HSBC has a 'reduce' call on Bajaj Housing Finance with the target price at Rs 100. Analysts said the housing finance company's quarterly AUM growth was healthy but high cost ratio and yield compression due to competition were drags on its results. They expect EPS growth to slow due to pressure on AUM growth, NIM compression, and normalisation of credit costs. Nomura has given a 'buy' rating on Anant Raj Industries but with a lowered target price at Rs 700 due to reduced fund-raising visibility. Analysts feel the stock is still an attractive bet despite a more conservative stance on the data center segment. They said internal accruals would fund 50% of the company's capex requirement. It has got a robust residential launch pipeline for FY26. Stay informed with the latest business news, updates on bank holidays and public holidays . Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!
Time of India
25-04-2025
- Business
- Time of India
Hot Stocks: 3 stocks that may give returns between 13-43%
A look at some of the latest stock recommendations by analysts . These stocks are expected to return between 13% and 43% as per analyst price targets . DIVI'S LABORATORIES by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Boria: The price (& size) of these hearing aids might surprise you Learn More Undo BROKERAGE: CITI Price Target: Rs 7,050 CMP: Rs 6,216 | Upside: 13% Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Orforglipron, Eli Lilly's oral diabetes drug, next addition in Divi's pipeline Potential to become primary supplier Company has announced $170-million capex, which Citi believes is primarily for GLP-1—medication to manage Type 2 diabetes and obesity Divi's could be a key player for Eli Lilly's next weight loss product—Retatrutide DEVYANI INTERNATIONAL BROKERAGE: BERNSTEIN Price Target: Rs 220 CMP: Rs 179 | Upside: 23% Reiterate positive view after acquiring majority stake in unlisted Sky Gate Hospitality, which owns Biryani By Kilo and other cloud kitchens Value accretive for Devyani as deal done at 2-2.5 times sales QSR (Quick Service Restaurant) chains at 4-6.6 times sales FY25 and FY26 earnings to be volatile because of M&A and growth moves Live Events ANANT RAJ BROKERAGE: NOMURA Price Target: Rs 700 CMP: Rs 488 | Upside: 43% Reiterate Buy rating but cut price target from Rs 750 to Rs 700 citing a more conservative stance on its data centre unit Company's 307 Mega Watt Data Centre target will be reached by FY32-33 as against earlier expectations of FY31 Valuations still attractive as earnings per share estimated to grow over 40% on a compounded basis over FY26-27
